News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Sharemaestro Market Watch Volume surge
The luxury-goods stock’s weekly damage now extends across one-, four- and twelve-week measures, while relative strength remains weak despite an active trend reading.
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Monte Rosa Therapeutics (GLUE) reported widening net losses for Q2 and the first half of 2026, marking a significant shift from prior-year profitability. This financial downturn, with a net loss of US$87.9 million for the six-month period, deepens the investment risk, highlighting the company's …
The State of Wyoming acquired a new position of 11,780 shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) valued at approximately $1.35 million during the second quarter. This comes as Kymera reported stronger-than-expected quarterly results with a significant revenue increase, although insiders sold a substantial amount …
Oppenheimer Asset Management Inc. has acquired a new position in SiteOne Landscape Supply, Inc. (NYSE:SITE), purchasing 26,740 shares valued at approximately $3.06 million. This investment comes amidst mixed analyst sentiment, with a consensus "Hold" rating despite the company missing recent quarterly earnings and revenue …
Oppenheimer Asset Management Inc. has initiated a new position in Tapestry, Inc. (NYSE:TPR) by purchasing 21,000 shares valued at approximately $3.07 million. This comes as Tapestry reported strong quarterly earnings, exceeding expectations with EPS of $1.32 and revenue of $1.88 billion, largely driven by …
GSA Capital Partners LLP recently acquired a new position of 23,257 shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) during the second quarter, valued at approximately $2.022 million. Other institutional investors have also adjusted their holdings in CORT, with 93.61% of the stock owned by hedge …
TPR Q2 Deep Dive: International Growth and Marketing Investments Shape Mixed Outlook Luxury fashion conglomerate Tapestry (NYSE:TPR) met Wall Street's revenue expectations in Q2 CY2026, with sales up 8.9% year on year to $1.88 billion. The company's outlook for the full year was close …
Sharemaestro market context Trend signal active 52 weeks +31.1% · Next-week setup positive 57.2%Focus Partners Advisor Solutions LLC recently acquired a new stake of 22,006 shares in Tapestry, Inc. (NYSE:TPR) during the second quarter, valued at approximately $3.22 million. This move comes as other institutional investors have also adjusted their positions in the luxury accessories retailer, with …
Wall Street Zen has upgraded Avalo Therapeutics (NASDAQ:AVTX) from a "sell" to a "hold" rating, though the consensus among other analysts remains a "Moderate Buy" with an average price target of $45.10. The company reported a quarterly loss of $0.83 per share, missing estimates. …
Wall Street Zen has upgraded Atara Biotherapeutics (NASDAQ:ATRA) from "Sell" to "Hold," reflecting an average "Hold" consensus among analysts with an average price target of $9.50. Despite the upgrade, ATRA shares opened down 4.9% at $8.09, with the company reporting a quarterly loss of …
Why Tapestry (TPR) Shares Are Getting Obliterated Today What Happened? Shares of luxury fashion conglomerate Tapestry (NYSE:TPR) fell 14.8% in the morning session after the luxury fashion company issued a disappointing fiscal 2027 revenue forecast that triggered a steep selloff, completely overshadowing its fourth-quarter …
This article provides a price-driven analysis for Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting weak near-term sentiment but strong mid and long-term outlooks. It details institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, and an exceptional risk-reward short …
Nektar Therapeutics' stock fell 4% following its Q2 2026 earnings report, despite progress in its autoimmune pipeline, notably rezpegaldesleukin. The market reacted negatively to the company's substantial cash burn, with a quarterly net loss exceeding US$40 million and trailing 12-month losses widening. While the …
This article analyzes Rapport Therapeutics Inc. (RAPP) using AI models to determine its effect on rotational strategy timing. Key findings suggest a strong sentiment supporting an overweight bias, with resistance being tested. The analysis provides specific institutional trading strategies, including position trading, momentum breakout, …
Vivos Therapeutics, Inc. (VVOS) reported a Q2 loss of $0.31 per share, which was better than the Zacks Consensus Estimate of a $0.42 loss. However, the company missed revenue estimates, posting $5.15 million against an expected $5.43 million. Despite beating EPS estimates two out …
An insider at Zevra Therapeutics (ZVRA) has filed a Form 144 notice to resell up to 42,666 common shares. These shares are linked to restricted stock units granted in June 2025 and are planned for potential sale on NASDAQ. The filing also references previous …
This article provides current stock price information for First Tracks Biotherapeutics, Inc. (TRAX) on MEXC, detailing its live price, market data, and recent performance. It also includes instructions on how to buy TRAX on MEXC and offers a company overview, including its focus on …
Iovance Biotherapeutics, Inc. stock has rallied over 130% in 2026, closing at $6.98, but is showing strong overbought signals across multiple timeframes with daily RSI at 73.02. While the daily trend remains bullish due to strong EMA alignment and positive MACD, the elevated RSI …
Search by ticker symbol or company name and select a result to open its chart.